Literature DB >> 18798571

PPARgamma agonists as a new class of effective treatment for ulcerative colitis.

Pierre Desreumaux1, Laurent Dubuquoy.   

Abstract

Entities:  

Year:  2009        PMID： 18798571     DOI： 10.1002/ibd.20765

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  5 in total

1.  Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration.

Authors:  Amir J Guri; Raquel Hontecillas; Josep Bassaganya-Riera
Journal:  Clin Nutr       Date:  2010-03-16       Impact factor: 7.324

2.  The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease.

Authors:  Amir J Guri; Saroj K Mohapatra; William T Horne; Raquel Hontecillas; Josep Bassaganya-Riera
Journal:  BMC Gastroenterol       Date:  2010-06-10       Impact factor: 3.067

3.  Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease.

Authors:  R Hontecillas; W T Horne; M Climent; A J Guri; C Evans; Y Zhang; B W Sobral; J Bassaganya-Riera
Journal:  Mucosal Immunol       Date:  2010-11-10       Impact factor: 7.313

4.  The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course.

Authors:  Jessica Mwinyi; Christa Grete-Wenger; Jyrki J Eloranta; Gerd A Kullak-Ublick
Journal:  PPAR Res       Date:  2012-02-14       Impact factor: 4.964

5.  Beneficial effects of THSG on acetic acid-induced experimental colitis: involvement of upregulation of PPAR-γ and inhibition of the Nf-Κb inflammatory pathway.

Authors:  Cheng Zeng; Jun-Hua Xiao; Mu-Jun Chang; Jia-Ling Wang
Journal:  Molecules       Date:  2011-10-12       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.